CLAUDE LAMARRE

Vice President, Finance

 
“Génome Québec receives most of its financial support from Genome Canada and the Québec government for the funding of research projects and the operation of its technology centres.”

As at March 31, 2015, our research portfolio included 30 genomic projects, and three technology centres are currently in operation. Génome Québec invested $57.4 million during the 2014-2015 fiscal year. This amount, combined with the $27.1 million invested by other partners, brings our overall injection of funds to $84.5 million, an increase of 39%.

 
 

Business volume generated by research projects during the fiscal year amounted to $63.3 million. This year, Génome Québec managed projects under nine competitions, the largest being Personalized Health and the new Fonds de partenariat pour un Québec innovant et en santé (FPQIS).   

The budget for projects underway totals $265 million, $92 million of which is still to be carried out.

 

For the year ended on March 31, 2015, sales from our technology centres totalled $16.5 million, up 8% compared to last year. The technology centres posted an excess of revenues over expenses of $1.4 million. The cumulative surplus of the McGill University and Génome Québec Innovation Centre totalled $2.9 million at the end of the year, an amount to be turned over to the institution in the coming fiscal year. 

General and administrative expenses, communications and outreach costs and committee expenses totalled $3.5 million this year. While this means an 11.1% increase compared to last year, these expenses represent 4.5% of total investments versus 5.3% last year. The increase is primarily due to expenses associated with the new FPQIS competition. Investment revenue reached $352,000, for a return of 1.62%. 

During the fiscal year, the excess of revenues over expenses totalled $522,000. Non-designated net assets rose by $361,000, and $1.2 million were attributed to activities, for a sum of $2.3 million on March 31, 2015. Net assets totalling $500,000 have once again been earmarked for the contingency and technological development funds, and a sum of $1.2 million has been set aside for activities related to research, commercialization of research results and researcher support.

Finally, Génome Québec has respected the terms and conditions in compliance with the contractual agreements it has signed with its major financial partners.

 

 

Marc LePage
President and CEO
Génome Québec

 

Claude Lamarre
Vice President, Finance 
Génome Québec